- Home
- FLUX vs CVKD Comparison
FLUX vs CVKD Comparison
Compare FLUX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUX
- CVKD
- Stock Information
- Founded
- FLUX N/A
- CVKD 2022
- Country
- FLUX United States
- CVKD United States
- Employees
- FLUX N/A
- CVKD N/A
- Industry
- FLUX Industrial Machinery/Components
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- FLUX Miscellaneous
- CVKD Health Care
- Exchange
- FLUX Nasdaq
- CVKD Nasdaq
- Market Cap
- FLUX 25.4M
- CVKD 29.5M
- IPO Year
- FLUX N/A
- CVKD 2023
- Fundamental
- Price
- FLUX $1.90
- CVKD $12.71
- Analyst Decision
- FLUX Strong Buy
- CVKD Strong Buy
- Analyst Count
- FLUX 2
- CVKD 1
- Target Price
- FLUX $6.00
- CVKD $32.00
- AVG Volume (30 Days)
- FLUX 132.4K
- CVKD 35.8K
- Earning Date
- FLUX 08-15-2025
- CVKD 08-06-2025
- Dividend Yield
- FLUX N/A
- CVKD N/A
- EPS Growth
- FLUX N/A
- CVKD N/A
- EPS
- FLUX N/A
- CVKD N/A
- Revenue
- FLUX $63,074,000.00
- CVKD N/A
- Revenue This Year
- FLUX $11.10
- CVKD N/A
- Revenue Next Year
- FLUX $12.66
- CVKD N/A
- P/E Ratio
- FLUX N/A
- CVKD N/A
- Revenue Growth
- FLUX N/A
- CVKD N/A
- 52 Week Low
- FLUX $1.15
- CVKD $5.70
- 52 Week High
- FLUX $4.75
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- FLUX 58.26
- CVKD 49.98
- Support Level
- FLUX $1.36
- CVKD $11.00
- Resistance Level
- FLUX $2.53
- CVKD $13.56
- Average True Range (ATR)
- FLUX 0.20
- CVKD 1.15
- MACD
- FLUX 0.06
- CVKD 0.25
- Stochastic Oscillator
- FLUX 52.14
- CVKD 80.97
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.